Gilead Sciences Reports Higher Year-over-Year Revenue Alongside a Profit-to-Loss Flip at the Parent Level in Both the Quarter and the Six-Month Window

Bottom line

- This earnings release covers GILEAD SCIENCES, INC. (ticker GILD) on a 10-Q filing for period-ended-2026-06-30, filed under accession 0000882095-26-000031 with CIK 0000882095. The disclosure presents a six-month year-to-date window alongside the three-month quarterly window, each with a prior-year comparative.

- Top-line revenue moved higher year-over-year in both windows. Revenue from Contract with Customer, Excluding Assessed Tax rose on both a the six months ended June 30, 2026 versus the six months ended June 30, 2025 basis and a the three months ended June 30, 2026 versus the three months ended June 30, 2025 basis, per $14,763,000,000, $13,749,000,000, $7,803,000,000, and $7,082,000,000. - Despite higher revenue, profitability lines flipped from profit to a loss on the parent level in both reporting windows.

Net Income (Loss) Attributable to Parent shows a profit in the six months ended June 30, 2025 and the three months ended June 30, 2025 but a loss in the six months ended June 30, 2026 and the three months ended June 30, 2026, per $3,275,000,000, $1,960,000,000, -$8,475,000,000, and -$10,496,000,000. - Operating Income (Loss) followed the same profit-to-loss transition in both windows, per $4,711,000,000, $2,474,000,000, -$7,808,000,000, and -$10,394,000,000. 45 per diluted share.

The catalog flags the current-period EPS values as directionally negative, consistent with the parent-level loss. - Management commentary frames forward-looking content with safe-harbor language covering revenue trends, liquidity, capital use, the One Big Beautiful Bill Act, government shutdowns, collaboration and licensing arrangements, patent and exclusivity matters, and ongoing litigation, with risk factors detailed in Item 1A. S.

S. components is presented for both three-month periods; line items include Epclusa and its authorized generic (sold through Asegua Therapeutics LLC) and other product families described in the cited disaggregation table. - Fair-value methodology for available-for-sale debt securities references Level 2 inputs using observable market data and third-party pricing services, while foreign currency derivative contracts are described with short maturities and counterparties rated A- or equivalent by S&P Global Ratings and Moody's Investors Service, Inc.

- The reader-facing takeaway is a top-line gain paired with a profit-to-loss flip across operating income, parent net income, and diluted EPS for both the quarter and the year-to-date window; The filing evidence does not attribute this change to any single cause.. - Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window. - The filing evidence contains no peer or industry comparison.

Financial performance

- For the three-month reporting period, Gilead reported Revenue from Contract with Customer, Excluding Assessed Tax of $7,803,000,000 USD, compared with $7,082,000,000 USD in the prior-year quarter — higher year over year on a top-line basis. The same line item for the six-month year-to-date window was $14,763,000,000 USD, versus $13,749,000,000 USD in the prior-year half, also higher year over year.

- Operating Income (Loss) moved in the opposite direction: the three-month period showed a loss of -$10,394,000,000 USD against a profit of $2,474,000,000 USD in the prior-year quarter, and the six-month window showed a loss of -$7,808,000,000 USD against a profit of $4,711,000,000 USD a year earlier. Both represent a profit-to-loss transition.

- Net Income (Loss) Attributable to Parent followed the same profit-to-loss pattern: a loss of -$10,496,000,000 USD for the quarter versus a profit of $1,960,000,000 USD a year earlier, and a loss of -$8,475,000,000 USD for the half-year versus a profit of $3,275,000,000 USD in the prior-year half.

- Earnings Per Share, Diluted traced the same trajectory: a loss of -$8.45 per diluted share USD/SHARES for the quarter against a profit of $1.56 per diluted share USD/SHARES a year earlier, and a loss of -$6.82 per diluted share USD/SHARES for the half-year against a profit of $2.61 per diluted share USD/SHARES in the prior-year half.

- In counter-evidence, the half-year operating cash line stayed positive year over year even as parent-level earnings swung from profit to loss: Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

- Management frames the figures on a generally accepted accounting principles basis for interim reporting, with normal recurring adjustments that they state are not necessarily indicative of full-year results, and notes that certain amounts may not sum or recalculate due to rounding. They also disclose that revenue is disaggregated by product family (for example, a category that includes Epclusa and an authorized generic, and another that includes ledipasvir/sofosbuvir, Hepcludex, Sovaldi, Viread and Vosevi).

- They further disclose impairment charges of a larger amount in the three-month period and a smaller amount in the six-month period, both tied to certain acquired in-process research and development assets, and reference fair-value hierarchy levels with no transfers between the cited tiers in the periods presented. Hepcludex (bulevirtide) received accelerated FDA approval in May of the current year, with the majority of the related contingent consideration reflected in financing activities.

- Causality for the swing from profit to loss across the income-statement lines is not addressed by the filing: The filing evidence does not attribute this change to any single cause.

- No forward guidance ranges, quarterly directional targets, or sell-side analyst expectations are disclosed in the filing evidence; comparisons are limited to the prior-year windows reported in the same statement. Peer or industry comparison data is also absent: The filing evidence contains no peer or industry comparison.

- Readers weighing the divergence between a higher revenue base and lower earnings can cross-check similar swing patterns in Acorn Energy, Inc. Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base as a structural reference point.

Operating drivers and segments

- The GILEAD SCIENCES, INC. filing on 10-Q for period-ended-2026-06-30 (accession 0000882095-26-000031) reports consolidated revenue of $7,803,000,000 USD for the three-month period the three months ended June 30, 2026, up against $7,082,000,000 USD for the three months ended June 30, 2025, under the authorized Revenue direction (period quarter compared with quarter_prior_year). - Year-to-date revenue of $14,763,000,000 USD for the six months ended June 30, 2026 sits against $13,749,000,000 USD for the six months ended June 30, 2025, under the authorized Revenue direction (period half_year compared with half_year_prior_year). - Despite the top-line increase, operating income flipped to a loss of -$10,394,000,000 USD for the three months ended June 30, 2026 versus a profit of $2,474,000,000 USD in the three months ended June 30, 2025, and to -$7,808,000,000 USD for the six months ended June 30, 2026 versus $4,711,000,000 USD in the six months ended June 30, 2025, both under the authorized Operating Income direction and authorized transition profit to loss (period compared with prior). - The standalone label "Operating drivers, segment evidence, and management claims versus independent analysis" cannot be tied to a finer product or geography breakdown from the catalog, because the only disaggregated context the filing evidence quotes (the Total revenues table for the three-month period and references to Asegua Therapeutics LLC within a product footnote) does not map to any FACT or REF key in this section. The filing evidence does not attribute this change to any single cause.

- Management frames the period through forward-looking statements about "overall trends; operating cost, product sales and revenue trends; liquidity and capital needs," expectations regarding products, product candidates, corporate strategy, financial projections, strategic investments, the use of capital, the impact of the One Big Beautiful Bill Act, U.S. government shutdowns, collaboration and licensing arrangements, patent protection, estimated loss of exclusivity, and ongoing litigation and investigation matters, with the safe-harbor language explicitly referencing Item 1A. - Management reiterates that interim financial information reflects "normal recurring adjustments … not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period," and that no material changes have occurred to the summary of business or significant accounting policies since the prior Annual Report. - Management also cautions readers to evaluate the risks described under Item 1A because "any of the risks contained herein could materially and adversely affect our business, results of operations and financial condition," and declines any obligation to update forward-looking statements other than as required. - Independent analysts can observe that reported revenue expanded while operating income transitioned profit to loss across both the quarter and the year-to-date window, a pattern mirrored in the parent-level earnings line and discussed alongside National Bankshares Posts Higher Year-over-Year Net Income and Diluted EPS for Both the Quarter and Year-to-Date Periods as a useful contrast case for revenue-up, earnings-down reporting. - The counter-evidence available in this section's catalog is Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window., which addresses the parent-level profit-to-loss transition alongside the cash-flow statements rather than the operating-income line itself, and is recorded here without further attribution to a single cause. The filing evidence does not attribute this change to any single cause.

Cash flow and capital

Reported cash generation strengthened in the year-to-date window. Net Cash Provided by Operating Activities for the six months ended June 30, 2026 reached $6,117,000,000 USD, higher than the $2,584,000,000 USD recorded for the six months ended June 30, 2025. Management's filings describe the period's interim financials as prepared in accordance with generally accepted accounting principles for interim financial information, with normal recurring adjustments that are not necessarily indicative of results for the full fiscal year. The improved cash conversion sits in contrast to a separate reported movement at the parent level, where Net Income (Loss) Attributable to Parent fell from profit to a loss on a year-over-year basis: Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.. The filing evidence does not attribute this change to any single cause.

Investing activities remained a use of cash. Net Cash Provided by (Used in) Investing Activities was -$8,577,000,000 USD for the six months ended June 30, 2026, lower than the -$2,531,000,000 USD outflow recorded in the six months ended June 30, 2025. Within that envelope, Payments to Acquire Property, Plant, and Equipment rose to $257,000,000 USD for the six months ended June 30, 2026, higher than $211,000,000 USD in the prior-year comparative. Disclosed investing narratives also reference the sale of all available-for-sale debt securities during the period, with proceeds partially funding acquisitions discussed in Note 6, and a recorded impairment charge on certain acquired in-process research and development assets.

Financing activities likewise reflected continued capital return. Net Cash Provided by (Used in) Financing Activities was -$1,895,000,000 USD for the six months ended June 30, 2026, higher than the -$4,993,000,000 USD outflow of the prior-year comparative. Capital return within that total split in opposite directions across the two principal programs. Payments of Dividends increased to $2,069,000,000 USD for the six months ended June 30, 2026, higher than $2,004,000,000 USD in the six months ended June 30, 2025. Payments for Repurchase of Common Stock, by contrast, moderated to $774,000,000 USD for the six months ended June 30, 2026, lower than $1,257,000,000 USD in the prior-year comparative. The filing evidence does not attribute this change to any single cause. A separate note discusses contingent consideration paid for a regulatory milestone, with a portion reflected in financing activities and the balance expected later in the fiscal year.

On the balance sheet side, Accounts Payable, Current stood at $674,000,000 USD as of the balance sheet date of June 30, 2026, and Long-term Debt, Excluding Current Maturities was $23,832,000,000 USD on the same date, both reported on the Condensed Consolidated Balance Sheets. Reported fair-value hierarchy disclosures note no transfers between the levels in the periods presented, providing a stable measurement backdrop for available-for-sale debt securities discussed in the cited note. The filing evidence contains no peer or industry comparison.

Peer and historical context

The filing evidence contains no peer or industry comparison. Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

Within GILEAD SCIENCES, INC.'s own historical record, the 10-Q filing for period-ended-2026-06-30 (filed under 0000882095-26-000031 for 0000882095, ticker GILD) lets us read off three reporting pairs — the three-month period versus the prior-year quarter, and the year-to-date six-month period versus the prior-year six months.

On the top line, Revenue from Contract with Customer, Excluding Assessed Tax moved higher in both windows. For the quarter, $7,803,000,000 USD compares against $7,082,000,000 USD for the three months ended June 30, 2025; the year-to-date comparison runs $14,763,000,000 USD against $13,749,000,000 USD for the six months ended June 30, 2025. Two cleanly positive-to-positive outcomes, with revenue expanding into the higher base both in the latest quarter and across the first half of the year.

Below revenue, the picture turns. Operating Income (Loss) flipped sign in the same two comparisons. The quarter shows -$10,394,000,000 USD against $2,474,000,000 USD, and the half-year shows -$7,808,000,000 USD against $4,711,000,000 USD. In both cases, the prior periods were profitable and the current periods are losses — a profit-to-loss transition at the operating level for both reporting windows.

Net Income (Loss) Attributable to Parent mirrors that profit-to-loss shift. The quarter compares -$10,496,000,000 USD with $1,960,000,000 USD; the half-year compares -$8,475,000,000 USD with $3,275,000,000 USD. Lower net lines now sit beneath higher revenue.

The cash flow statement tells a separate story. Net Cash Provided by (Used in) Operating Activities strengthened across the year-to-date period: $6,117,000,000 USD against $2,584,000,000 USD for the six months ended June 30, 2025. Both numbers are positive and the current reading is the higher of the two — operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

For the analyst, the key comparative reading is that revenue growth and operating cash generation strengthened at the same time as operating and net results turned negative. The filing evidence does not attribute this change to any single cause.

No peer or industry comparison is available in the filing evidence, so cross-issuer benchmarking — for context a reader might otherwise expect from filings such as Acorn Energy, Inc. Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base — cannot be drawn here without outside numbers. The historical comparison stays internal to the two paired periods above.

Scenario analysis

- A revenue line that grew year over year on both a quarter and a half-year basis, paired with a parent-level earnings line that swung from profit to loss across the same comparisons, frames the central tension inside GILEAD SCIENCES, INC.'s period-ended-2026-06-30 filing on 10-Q under accession 0000882095-26-000031. - Reported facts: Revenue from Contract with Customer, Excluding Assessed Tax was $7,082,000,000 USD for the three months ended June 30, 2025 and $7,803,000,000 USD for the three months ended June 30, 2026 (higher than the prior period, per the authorized year-over-year direction), and was $13,749,000,000 USD for the six months ended June 30, 2025 and $14,763,000,000 USD for the six months ended June 30, 2026 (also higher than the prior period). - Counter-evidence on the same filing's earnings line: Net Income (Loss) Attributable to Parent was $1,960,000,000 USD for the three months ended June 30, 2025 and -$10,496,000,000 USD for the three months ended June 30, 2026 — a decrease, a loss rather than a profit — and was $3,275,000,000 USD for the six months ended June 30, 2025 and -$8,475,000,000 USD for the six months ended June 30, 2026 — also a decrease and a loss rather than a profit. - Management explanation and causality are not attributed: The filing evidence does not attribute this change to any single cause.. - Analyst inference for the base case reads this combination as a top-line that is still expanding while bottom-line profitability is under pressure, leaving the earnings trajectory as the open variable rather than the demand picture. - Operating cash generation is the relevant counterweight: Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.. - Unknowns in this filing's filing evidence include any peer or industry frame and any segment-level reconciliation: The filing evidence contains no peer or industry comparison. and The filing evidence does not disclose segment-level detail for this dimension..

- Top-line momentum continues: Revenue from Contract with Customer, Excluding Assessed Tax is higher than the prior period on both the three months ended June 30, 2026 versus the three months ended June 30, 2025 and the six months ended June 30, 2026 versus the six months ended June 30, 2025 per the authorized year-over-year directions, leaving demand as the stabilizer if it persists. - Earnings normalization: if parent-level earnings stop being a loss and return toward the prior-period profit reported for the three months ended June 30, 2025 ($1,960,000,000 USD) and the six months ended June 30, 2025 ($3,275,000,000 USD), the reported gap between revenue growth and income decline resolves. - Cash discipline holds: Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window. supports the read that the cash line did not deteriorate alongside the income line over the half-year window. - Tailwinds inside the filing narrative include the Hepcludex accelerated approval noted in the source narrative, the prior-period exit from available-for-sale debt securities, and the maturity profile of the cash-flow hedge book (covered in Note 6 and Note 7), each of which can be revisited in the upside path. - Reader-facing caveat: no cause is assigned to the earnings decline; The filing evidence does not attribute this change to any single cause..

- Earnings pressure persists or deepens: Net Income (Loss) Attributable to Parent is a loss on both the three months ended June 30, 2026 (-$10,496,000,000 USD) and the six months ended June 30, 2026 (-$8,475,000,000 USD) versus a profit in the prior periods, per the authorized profit-to-loss transition in both comparisons. - Top-line slowdown: although Revenue from Contract with Customer, Excluding Assessed Tax is higher than the prior period on both windows, the qualifier in this scenario is a deceleration from the rates already authorized; magnitude itself is not asserted here. - The acquisition-related items cited in Note 6 and the fair-value disclosures in Note 7 are the recurring references that the filing ties to the income line; an investor weighing the downside path will watch those notes in future periods. - Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window. is the only authorized counterweight; The filing evidence does not attribute this change to any single cause. marks the absence of a single named driver.

Risks and what to watch

The single most consequential risk frame for GILEAD SCIENCES, INC. (GILD) this period is the swing in parent-level earnings against still-positive revenue. Reported revenue from contracts with customers was positive for both the three-month reporting period ($7,803,000,000) and the six-month year-to-date period ($14,763,000,000), and it moved higher year over year in both windows — revenue rose versus the prior-year quarter ($7,082,000,000) and versus the prior-year year-to-date period ($13,749,000,000). Yet net income attributable to parent printed as a loss for both the quarter (-$10,496,000,000) and the year-to-date period (-$8,475,000,000), reversing prior-year profits of $1,960,000,000 and $3,275,000,000 in the respective comparison windows. That divergence — top-line growth with bottom-line losses — is the dominant risk narrative going into the next period, and The filing evidence does not attribute this change to any single cause. applies to the earnings swing itself.

Counter-evidence is meaningful here. Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window. Net Cash Provided by (Used in) Operating Activities for the six-month year-to-date period remained positive and increased versus the prior-year comparative, even as parent-level earnings moved from profit to a loss over the longer reporting window. Investing activity used more cash than the prior year-to-date period (a larger negative figure), and financing activity also used more cash than the prior year-to-date period (a larger negative figure). Capital return policy is still active: payments of dividends rose versus the prior year-to-date period, while payments for repurchase of common stock decreased versus the prior year-to-date period. Property, plant, and equipment spending increased versus the prior year-to-date period. Taken together, the operating cash line partially offsets the headline earnings risk and suggests liquidity was not the binding constraint on the period.

Several material unknowns remain. The filing does not disclose segment-level revenue or operating-income detail, so The filing evidence does not disclose segment-level detail for this dimension.. Peer and industry comparisons are likewise absent, so The filing evidence contains no peer or industry comparison.. Beyond legal-proceedings commentary in Item 1 and risk-factor updates in Item 1A, the 10-Q for period-ended-2026-06-30 (accession 0000882095-26-000031, CIK 0000882095) does not surface a discrete named driver for the parent-level loss; the equity-securities, derivatives, and available-for-sale debt discussion (see Note 6 and Note 7, with fair-value hierarchy detail in Level 1, Level 2, and Level 3) speaks to portfolio positioning and hedging rather than to the earnings bridge.

Metrics to watch next period: whether net income attributable to parent returns to positive territory in the quarter and year-to-date windows, the trajectory of payments for repurchase of common stock relative to the prior year-to-date period, and whether operating cash generation continues to widen against prior-year levels even if GAAP earnings remain negative. Investors comparing broad year-over-year declines across every earnings line can benchmark against Acorn Energy, Inc. Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base.